Difference between revisions of "Irinotecan (Camptosar)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
|||
| Line 13: | Line 13: | ||
*[http://chemocare.com/bio/irinotecan.asp Irinotecan (Camptosar) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/irinotecan.asp Irinotecan (Camptosar) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/irinotecan.asp Irinotecan (Camptosar) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/irinotecan.asp Irinotecan (Camptosar) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/irinotecan-patient-drug-information Irinotecan (Camptosar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/irinotecan-patient-drug-information Irinotecan (Camptosar) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/irinotecan-patient-drug-information Irinotecan (Camptosar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/irinotecan-patient-drug-information Irinotecan (Camptosar) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 6/14/1996: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 15:35, 6 June 2013
Also known as Camptothecin-11, CPT-11.
General information
Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible
single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase
I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Irinotecan (Camptosar) patient drug information (Chemocare)[3]
- Irinotecan (Camptosar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/14/1996: Initial FDA approval